Earnings Beat at Alkermes

Zacks

Alkermes’ (ALKS) adjusted earnings (including stock-based compensation expense but excluding other special items) of 24 cents per share for the 3-month period ended Jun 30, 2013 compared unfavorably with the year-ago earnings of 32 cents per share.

Results in the reported period were hurt by lower revenues and higher operating expenses. The Zacks Consensus Estimate hinted at earnings of $0.16 per share.

Total revenue for the 3-month period ended Jun 30, 2013 declined 9% year over year to $138.6 million. Results in the year-ago quarter were aided by the inclusion of intellectual property license revenue worth $200 million, which is not related to key development programs. Revenues surpassed the Zacks Consensus Estimate of $135 million.
    
For the 3-month period ended Jun 30, 2013, Alkermes recorded $56.2 million (up 15.6% year over year) of manufacturing and royalty revenues from its long-acting atypical antipsychotic franchise comprising Risperdal Consta and Invega Sustenna/Xeplion.

The drugs are marketed by Johnson & Johnson (JNJ). Alkermes recorded manufacturing and royalty revenues of $19.9 million (up 15.7% year over year) from Ampyra (EU trade name: Fampyra). Alkermes earned royalty revenues of $16.4 million from type II diabetes treatment Bydureon. Bydureon is co-marketed with Bristol-Myers Squibb Company (BMY).

Vivitrol, a legacy Alkermes product, performed well during the 3-month period. Sales of the product climbed approximately 40% year over year to $17.4 million. Alkermes also earned revenues from TriCor 145 ($4.1 million) and Ritalin LA/Focalin XR franchise ($11.2 million) and Verelan ($6.5 million). Reported total expenses were $125.1 million during the period, up from the year-ago figure of $120.1 million.

We note that in May 2013, Alkermes had announced a change in its fiscal year-end from Mar 31 to Dec. 31. The company maintained its outlook (provided in May) for the 9-month period starting from Apr 2013 to Dec 2013. The company still expects adjusted earnings for the period to be in the range of $0.61 - $0.75 per share. Revenues for the 9-month period are projected in the range of $395 - $425 million.

Alkermes, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). However, another stock which appears to be more attractive in the biopharma space is Actelion Ltd. (ALIOF) with a Zacks Rank #1 (Strong Buy). 

Read the Full Research Report on ALKS

Read the Full Research Report on BMY

Read the Full Research Report on ALIOF

Read the Full Research Report on JNJ

Zacks Investment Research



More From Zacks.com
View Comments